Safety and Efficacy Study of Dysport RU and Glabellar Lines - Global
Back

Safety and Efficacy Study of Dysport RU and Glabellar Lines

- 05 September 2024 - 1 mins read

The primary objective is to assess the dose response versus placebo of a single treatment of Dysport RU (Dysport RU, Ready to Use, for injection), for the improvement in appearance of moderate to severe glabellar lines at maximum frown.

Related Clinical Trials

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
05 September 2024 1 mins read

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
05 September 2024 1 mins read

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
05 September 2024 1 mins read

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
05 September 2024 1 mins read

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
05 September 2024 1 mins read

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
05 September 2024 1 mins read

Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
05 September 2024 1 mins read

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
05 September 2024 1 mins read

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
05 September 2024 1 mins read

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
05 September 2024 1 mins read

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction